Abstract:Background: Despite biochemically responding to injectable somatostatin receptor ligands (iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess maintenance of biochemical response and symptomatic control with oral octreotide capsules versus iSRLs in patients with acromegaly who previously tolerated and responded to both. Methods: This global, open-label, randomised controlled phase 3 trial was done in 29 clinical sites in Austria, France, Germany, Hungary, Italy, Lithuania, Russia, Serbia, Spain, and the USA. Eligible patients were adults aged 18-75 years with acromegaly who were receiving iSRLs (long-acting octreotide or lanreotide autogel) for at least 6 months before baseline with a stable dose for at least 4 months, and were deemed to be biochemically responding (insulin-like growth factor I [IGF-I] <1·3 × upper limit of normal [ULN] and mean integrated growth hormone <2·5 ng/mL). In the 26-week run-in phase, all patients received oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day). Eligibility for the randomised treatment phase was completion of the run-in phase as a biochemical responder (IGF-I <1·3 × ULN and mean integrated growth hormone <2·5 ng/mL at week 24) and investigator assessment of acromegaly being adequately controlled. Patients were randomly assigned (3:2) to oral octreotide capsules or iSRL at the same dose and interval as before enrolment. Randomisation and drug dispensing were conducted through a qualified randomisation service provider (eg, interactive web or voice response system). The primary endpoint was a non-inferiority assessment (margin -20 percentage points) of proportion of participants maintaining biochemical response throughout the randomised treatment phase (IGF-I <1·3 × ULN using time-weighted average; assessed by comparing the lower bound of the 2-sided 95% CI for the difference in biochemical response between groups). IGF-I was assessed once a month during the run-in and randomised treatment phases (single sample). Efficacy and safety assessments were performed on the randomised population. This trial is registered with ClinicalTrials.gov, NCT02685709. Findings: Between Feb 11, 2016, and Aug 20, 2020, 218 patients were assessed for eligibility. 72 patients were excluded, and 146 participants were enrolled into the run-in phase. 116 patients completed the run-in phase and 30 participants discontinued treatment. 92 participants were randomly assigned to oral octreotide (n=55) or iSRL (n=37). 50 (91%) of 55 participants who received oral octreotide (95% CI 44-53) and 37 (100%) of 37 participants who received iSRLs (34-37) maintained biochemical response. The lower bound of the 2-sided 95% CI for the adjusted difference in proportions between the two treatment groups achieved the prespecified non-inferiority criterion of -20% (95% CI -19·9 to 0·5). 19 (35%) of 55 participants in the oral octreotide group and 15 (41%) of 37 participants in the iSRL group had treatment-related adverse events; the most common of which in both groups were gastrointestinal. Interpretation: Oral octreotide was non-inferior to iSRL treatment, and might be a favourable alternative to iSRLs for many patients with acromegaly. Funding: Chiasma. Translation: For the Russian translation of the abstract see Supplementary Materials section.

Response of Patients with Acromegaly to Long-acting Octreotide with regard to Regression of Pituitary Adenoma, Growth Hormone and Insulin-like Growth Factor-1

Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Treatment of acromegaly with oral octreotide

The effect of octreotide treatment on somatic and psychological symptoms of acromegaly

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution

Carbohydrate Tolerance and Serum Lipids in Acromegaly Before and During Treatment with High Dose Octreotide

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Author Response for "2010 Versus the 2000 Consensus Criteria in Patients with Normalised Insulin‐like Growth Factor 1 after Transsphenoidal Surgery Has High Predictive Values for Long‐term Recurrence‐free Survival in Acromegaly"

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment

Current therapy and drug pipeline for the treatment of patients with acromegaly

Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study

Medical treatment of acromegaly - When the tumor size matters: A narrative review

The Value of an Acute Octreotide Suppression Test in Predicting Short-Term Efficacy of Somatostatin Analogues in Acromegaly

Presurgical Treatment with Somatostatin Analogues in Growth Hormone-Secreting Pituitary Adenomas: A Long-Term Single-Center Experience

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy

Effect of Presurgical Long-Acting Octreotide Treatment in Acromegaly Patients with Invasive Pituitary Macroadenomas: A Prospective Randomized Study

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

Comparative Efficacy of Medical Treatment for Acromegaly: A Systematic Review and Network Meta-Analysis of Integrated Randomized Trials and Observational Studies

A single-center experience of transsphenoidal endoscopic surgery for acromegaly in 73 patients: results and predictive factors for remission